iNtRON Biotechnology KRX:048530KOSDAQ
인트론바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h2
Articles, 7 days2
DART filings, 7 days0
Articles tracked2since Sep 11
In Q2 2026, iNtRON Biotechnology reported revenue of ₩2.0bn, up 66.0% year on year, and an operating loss of ₩1.6bn. iNtRON Biotechnology (인트론바이오) appeared in 2 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 2 articles. It was most often mentioned alongside Bnc Korea.
iNtRON Biotechnology quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩2.0bn | +66.0% | −₩1.6bn | −₩2.3bn |
| Q1 2026 | ₩1.9bn | +58.7% | −₩2.2bn | −₩2.3bn |
| Q4 2025 derived | ₩1.7bn | +12.0% | −₩2.0bn | −₩4.1bn |
| Q3 2025 | ₩1.6bn | +34.3% | −₩2.1bn | −₩1.7bn |
| Q2 2025 | ₩1.2bn | -31.0% | −₩2.0bn | −₩1.1bn |
| Q1 2025 | ₩1.2bn | -37.9% | −₩1.8bn | −₩2.0bn |
| Q4 2024 derived | ₩1.5bn | -59.1% | −₩1.3bn | −₩1.5bn |
| Q3 2024 | ₩1.2bn | -27.7% | −₩1.6bn | −₩1.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
iNtRON Biotechnology top stories 2 weeks, by number of outlets
- 1
- 2
